Article
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
The oncologist - 1 Jan 2007
Sequist Lecia V, Joshi Victoria A, Jänne Pasi A, Muzikansky Alona, Fidias Panos, Meyerson Matthew, Haber Daniel A, Kucherlapati Raju, Johnson Bruce E, Lynch Thomas J
Abstract excerpt
Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with clinical response and prolonged survival in patients with non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). We began screening patients for somatic EGFR mutations by DNA sequencing as part of clinical care in 2004. We performed a retrospective cohort study of 278 patients with NSCLC...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
